Virus titres in infected Vero cells
Cell-based study · CVB3-infected Vero cells [1]
CVB3-infected Vero cells were treated with PSI-6206. Virus titres measured by the TCID50 assay had a reported result of 1.8-fold at the highest concentration tested compared with untreated virus-infected cells.
| Endpoint | Reported result | Reference |
|---|---|---|
| virus titres were determined by the TCID50 assay | viral titre 1.8-fold | [1] |
Literature-Reported Treatment Conditions
- Exposure duration
- 24 hpi
- Method
- treated with dasabuvir and PSI-6206 at the indicated concentration, respectively
- Vehicle
- dimethyl sulfoxide (DMSO)
- Co-treatment
- Other interventions in this design: CVB3 MOI = 1. Compound effect isolated by the comparison: as compared to untreated virus-infected cells.
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: PSI-6206
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Virus, cell lines and compounds (S3); Results > Dasabuvir and PSI-6206 are potent inhibitors of CVB3 replication (S25, S32, S33)
virus titres were determined by the TCID50 assay: virus titres were determined by the TCID50 assay; comparator: untreated virus-infected cells — Results > Dasabuvir and PSI-6206 are potent inhibitors of CVB3 replication (S25, S33)